Tech Company Financing Transactions
Dialybrid Funding Round
Dialybrid, based in Cantù (CO), secured $17 million from XGen Ventures and CDP Venture Capital.
Transaction Overview
Company Name
Announced On
9/22/2026
Transaction Type
Venture Equity
Amount
$17,000,000
Round
Series A
Investors
XGen Ventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to advance the clinical development of its Silkothane Arteriovenous Graft as a hemodialysis vascular access, and for preclinical development of the Silkothane® material in other vascular applications.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
Via Antonio Vivaldi 32/A
Cantù (CO), 22063
Italy
Cantù (CO), 22063
Italy
Phone
Website
Email Address
Overview
Dialybrid inherits the R&D experience of Bioengineering Laboratories Srl in relation to Advanced Materials, with the aim of developing a novel semi-degradable vascular access for hemodialysis, based on silk fibroin and polyurethane (an innovative material called Silkothane®).
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Francesco Greco
Chief Technical Officer
Stefania Riboldi
Browse more venture capital transactions:
Prev: 9/22/2026: Amber Electric venture capital transaction
Next: 9/23/2026: Mojave Energy Systems venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to record all VC transactions involving tech companies. VC transactions on this site are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs